Try a new search

Format these results:

Searched for:

in-biosketch:true

person:cerfor01

Total Results:

399


Commentary: Temerity trumps dogma: The dangerous road of innovation [Editorial]

Cerfolio, Robert J
PMCID:8501199
PMID: 34647090
ISSN: 2666-2507
CID: 5068002

Pathological complete response after neoadjuvant treatment determines survival in esophageal squamous cell carcinoma patients (NEOCRTEC5010)

Shen, Jianfei; Kong, Min; Yang, Hong; Jin, Ke; Chen, Yuping; Fang, Wentao; Yu, Zhentao; Mao, Weimin; Xiang, Jiaqing; Han, Yongtao; Chen, Zhijian; Yang, Haihua; Wang, Jiaming; Pang, Qingsong; Zheng, Xiao; Yang, Huanjun; Li, Tao; Zhang, Xu; Li, Qun; Wang, Geng; Mao, Teng; Guo, Xufeng; Lin, Ting; Liu, Mengzhong; Ma, Dehua; Ye, Minhua; Wang, Chunguo; Wang, Zheng; Brunelli, Alessandro; Cerfolio, Robert J; D'Journo, Xavier Benoit; Fernando, Hiran C; Lordick, Florian; Fu, Jianhua; Chen, Baofu; Zhu, Chengchu
Background/UNASSIGNED:Few studies have exclusively investigated the value of pathological complete response (pCR), in esophageal squamous cell carcinoma (ESCC) patients, although it is a clinically significant parameter to evaluate the impact of neoadjuvant chemoradiotherapy (nCRT) on treatment outcome after surgery. The aim of our study was to explore the relationship between pCR after nCRT and survival among patients with local ESCC. Methods/UNASSIGNED:All patients receiving nCRT followed by surgery in NEOCRTEC5010-trial (NCT01216527) were included. Non-pCR patients were classified into three subgroups: ypTanyN0M0, ypT0NanyM0 and ypTanyNanyM0. The Kaplan-Meier method with log-rank test was employed to evaluate disease-free survival (DFS) and overall survival (OS). Multivariate regression analysis was performed using a Cox proportional hazards model to identify clinicopathological parameters associated with pCR. Results/UNASSIGNED:69.2 months; HR, 2.70; 95% CI: 1.48-4.92; P=0.001). The 5-year OS and DFS of the pCR group were 79.3% and 77% respectively, compared to 54.8% and 51.2%, respectively, in the non-pCR group. The results showed that the OS and DFS of the ypTanyN0M0 group were better than those of the ypT0NanyM0 group and the ypTanyNanyM0 group. We also found that the number of dissected lymph nodes and pCR were independent risk factors for DFS and OS rates. Conclusions/UNASSIGNED:pCR after nCRT is an important prognostic indicator of OS and DFS in patients with ESCC. In addition, lymph-node status could represent an important parameter in the prognostic evaluation of esophageal cancer patients.
PMCID:8576689
PMID: 34790722
ISSN: 2305-5839
CID: 5049302

Beyond the learning curve: a review of complex cases in robotic thoracic surgery

Geraci, Travis C; Scheinerman, Joshua; Chen, David; Kent, Amie; Bizekis, Costas; Cerfolio, Robert J; Zervos, Michael D
The number of thoracic surgery cases performed on the robotic platform has increased steadily over the last two decades. An increasing number of surgeons are training on the robotic system, which like any new technique or technology, has a progressive learning curve. Central to establishing a successful robotic program is the development of a dedicated thoracic robotic team that involves anesthesiologists, nurses, and bed-side assistants. With an additional surgeon console, the robot is an excellent platform for teaching. Compared to current methods of video-assisted thoracoscopic surgery (VATS), the robot offers improved wristed motion, a magnified, high definition three-dimensional vision, and greater surgeon control of the operation. These advantages are paired with integrated adjunctive technology such as infrared imaging. For pulmonary resection, these advantages of the robotic platform have translated into several clinical benefits, such as fewer overall complications, reduced pain, shorter length of stay, better postoperative pulmonary function, lower operative blood loss, and a lower 30-day mortality rate compared to open thoracotomy. With increased experience, cases of greater complexity are being performed. This review article details the process of becoming an experienced robotic thoracic surgeon and discusses a series of challenging cases in robotic thoracic surgery that a surgeon may encounter "beyond the learning curve". Nearly all thoracic surgery can now be approached robotically, including sleeve lobectomy, pneumonectomy, resection of large pulmonary and mediastinal masses, decortication, thoracic duct ligation, rib resection, and pulmonary resection after prior chest surgery and/or chemoradiation.
PMCID:8575821
PMID: 34795964
ISSN: 2072-1439
CID: 5049642

Managing Scarcity: Innovation and Resilience During the COVID-19 Pandemic

Pozzi, Natalie; Zuckerman, Aaron; Son, Joohee; Geraci, Travis C; Chang, Stephanie H; Cerfolio, Robert J
The Coronavirus Disease 2019 (COVID-19) pandemic remains a disruptive force upon the health care system, with particular import for thoracic surgery given the pulmonary pathophysiology and disease implications of the virus. The rapid and severe onset of disease required expedient innovation and change in patient management and novel approaches to care delivery and nimbleness of workforce. In this review, we detail our approaches to patients with COVID-19, including those that required surgical intervention, our expedited and novel approach to bronchoscopy and tracheostomy, and our expansion of telehealth. The pandemic has created a unique opportunity to reflect on our delivery of care in thoracic surgery and apply lessons learned during this time to "rethink" how to optimize resources and deliver excellent and cutting-edge patient care.
PMCID:8551480
PMID: 34722628
ISSN: 2296-875x
CID: 5037792

Can we sell something people don't want?

Cerfolio, Robert J.
SCOPUS:85115097817
ISSN: 2519-0792
CID: 5009692

Robotic right upper lobectomy: Twelve steps

Sasankan, Prabhu; Chang, Stephanie; Cerfolio, Robert
PMCID:8311674
PMID: 34318270
ISSN: 2666-2507
CID: 4966002

Outcomes of robotic surgery in patients with pulmonary nontuberculous mycobacterial disease [Meeting Abstract]

Mcguire, E L; Saini, S; Luoma, K; Zervos, M; Cerfolio, R J; Addrizzo-Harris, D J
Rationale: Treatment for patients with pulmonary nontuberculous mycobacterial (NTM) disease includes long, multi-drug, and toxic medication regimens. Despite medical therapy, the rate of sputum culture conversion is low. Surgical resection is an alternative treatment for patients with localized or refractory NTM infection. Traditionally, resection of the affected lung was achieved via open thoracotomy. Robot-assisted surgery is less invasive and similarly effective, but has not been used routinely in this population. To our knowledge, this is the first report of robotic surgery for patients with complex NTM disease.
Method(s): Using the electronic medical record we identified patients with NTM disease that underwent robotic anatomic pulmonary resection by an experienced surgeon. All surgeries were done at NYU Langone Medical Center between August 2017 and February 2020. We collected data on demographics, NTM species, antibiotic course, pre- and post-operative sputum cultures, and surgical complications.
Result(s): We identified 8 patients that met the criteria. 100% of the patients were female and 88% were white. Mean age at time of surgery was 53 years. The most common indication for surgery was cavitary disease, followed by failure of medical therapy, and hemoptysis. All of the patients had pre-operative sputum cultures positive Mycobacterium avium complex. Prior to surgery, 63% of patients required IV antibiotics. Lobectomy was the most common operation performed and none of the surgeries were converted to open thoracotomy. There were no post-operative bleeds requiring transfusion, pneumonias, pneumothoraces, or bronchopleural fistulas. One patient had an air leak > 5 days. None of the patients required an ICU stay and the median length of hospital stay was 2.5 days. There were no deaths. Patients were considered cured if they had sputum culture conversion or no longer required antibiotics. Partial cure was defined as symptom improvement or de-escalation of medical regimen. Six of the patients were completely cured, one patient was partially cured, and one patient was lost to follow-up.
Conclusion(s): Surgical resection for patients with complex NTM disease can be performed using minimally invasive, robotic techniques safely and without the need for conversion to open thoracotomy, blood transfusions, or ICU stay. In this small cohort of patients, robotic surgery had a high rate of cure, few post-operative complications, and a short length of hospital stay. Larger studies can assist with validating robotic surgery as the preferred approach in these patients
EMBASE:635306725
ISSN: 1535-4970
CID: 4915762

Systematic Review of Interventions to Reduce Operating Time in Lung Cancer Surgery

Hoefsmit, Paulien C; Cerfolio, Robert J; de Vries, Ralph; Dahele, Max; Zandbergen, H Reinier
Introduction/UNASSIGNED:Operating rooms are a scarce resource but often used inefficiently. Operating room efficiency emerges as an important part of maximizing surgical capacity and productivity, minimizing delays, and optimizing lung cancer outcomes. The operative time (time between patient entering and leaving the operating room) is discrete and the one that the surgical team can most directly influence. We performed a systematic review to evaluate the literature and identify methods to improve the efficiency of the intraoperative phase of operations for lung cancer. Methods/UNASSIGNED:A literature search (in PubMed, Embase, Cochrane, and Scopus) was performed from inception up to March 9, 2020, according to the methodology described in the Preferred Reporting Items for Systematic Reviews and Meta-Analysis (PRISMA) statement. Results/UNASSIGNED:We identified 3 articles relevant to the intraoperative phase of lung cancer operating room efficiency. All 3 were consistent in showing clinically relevant time reductions in the intraoperative phase or procedures relevant to this phase. The authors demonstrated that the application of various improvement methodologies resulted in a substantial reduction in operative time, which was associated with a reduction in complications, and improved staff morale. Conclusions/UNASSIGNED:Our systematic review found that various improvement methodologies have the potential to significantly reduce operative time for lung cancer surgery. This increases the value of lung cancer surgery. These findings are consistent with the wider literature on improving surgical efficiency.
PMCID:7970684
PMID: 33795942
ISSN: 1179-5549
CID: 4875542

Postoperative Air Leaks After Lung Surgery: Predictors, Intraoperative Techniques, and Postoperative Management

Geraci, Travis C; Chang, Stephanie H; Shah, Savan K; Kent, Amie; Cerfolio, Robert J
Postoperative air leak is one of the most common complications after pulmonary resection and contributes to postoperative pain, complications, and increased hospital length of stay. Several risk factors, including both patient and surgical characteristics, increase the frequency of air leaks. Appropriate intraoperative tissue handling is the most important surgical technique to reduce air leaks. Digital drainage systems have improved the management of postoperative air leak via objective data, portability, and ease of use in the outpatient setting. Several treatment strategies have been used to address prolonged air leak, including pleurodesis, blood patch, placement of endobronchial valves, and reoperative surgery.
PMID: 33926669
ISSN: 1558-5069
CID: 4873812

Dynamic Management of Lung Cancer Care During Surging COVID-19

Wang, Annie; Chang, Stephanie H; Kim, Eric J; Bessich, Jamie L; Sabari, Joshua K; Cooper, Benjamin; Geraci, Travis C; Cerfolio, Robert J
Management of patients with lung cancer continues to be challenging during the COVID-19 pandemic, due to the increased risk of complications in this subset of patients. During the COVID-19 surge in New York City, New York University Langone Health adopted triage strategies to help with care for lung cancer patients, with good surgical outcomes and no transmission of COVID-19 to patients or healthcare workers. Here, we will review current recommendations regarding screening and management of lung cancer patients during both a non-surge phase and surge phase of COVID-19.
PMCID:8059638
PMID: 33898509
ISSN: 2296-875x
CID: 4852952